Supplier News: WuXi Biologics, PCI Pharma Services & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring WuXi Biologics, Thermo Fisher Scientific, and PCI Pharma Services, Mikart and Benuvia. Biologics Manufacturing * WuXi Biologics Announces Structural Completion of Microbial Mfg Facility  * Thermo Fisher…

Global Briefs: Chiesi, Lilly, AbbVie & More 
By

By
A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Chiesi Group, Eli Lilly and Company, AbbVie and Teva. Highlights below.   For the latest news roundup on small and Emerging Pharma companies,…

Biotech Briefs: Seaport, Avalyn & Hemab 
By

By
The latest from small and Emerging Pharma companies featuring Seaport Therapeutics, Avalyn Pharma & Hemab Therapeutics.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * Seaport Announces $212-M IPO To Support…

AbbVie Investing $1.4 Bn for a New Mfg Campus in North Carolina 
By

By
AbbVie has announced a $1.4-billion investment to build a new 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The investment is part of the company’s $100-billion, 10-year capital investment plan in the US, which includes R&D and manufacturing,…

Merck & Co., Google in $1-Bn AI Pact 
By

By
Merck & Co. and Google Cloud have announced a multi-year partnership, worth up to $1 billion, to enhance Merck’s digital backbone in artificial intelligence (AI) by deploying an agentic AI platform across Merck’s research & development (R&D), manufacturing, commercial, and corporate functions.  The partnership includes…

Lilly To Acquire Kelonia Therapeutics in $7-Bn Deal 
By

By
Eli Lilly and Company has agreed to acquire Kelonia Therapeutics, a Boston-based clinical-stage bio/pharmaceutical company specializing in in vivo gene delivery, in a $7-billion deal ($3.25 billion upfront and $3.75 billion in milestone payments).  Kelonia has developed a proprietary in vivo gene-placement system, iGPS, which uses specially engineered…

Servier Completes $2.5 Bn Acquisition of Day One Biopharmaceuticals 
By

By
Servier, a French bio/pharmaceutical company, has completed its $2.5-billion acquisition of Day One Biopharmaceuticals, a Brisbane, California-based bio/pharmaceutical developing oncology drugs. The companies had announced the acquisition last month (March 2026).   Day One’s portfolio…

Supplier News: Evonik, Alcami, Tjoapack, Piramal & More  
By

By
The latest from CDMOs, CMOs, and suppliers featuring Evonik, Alcami, Tjoapack, Piramal Pharma, Ajinomoto Bio-Pharma Service, and Avantor.   Chemical/Chemical API Manufacturing * Piramal Pharma, Ajinomoto Bio-Pharma Services Form Strategic Collaboration in ADCsBiologics…

Global Briefs: Biogen, Asahi Kasei, UCB & More 
By

By
A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring UCB, Amneal, Biogen and Asahi Kasei. Highlights below.   For the latest news roundup on small and Emerging Pharma…

Biotech Briefs: Ray Therapeutics & Tortugas 
By

By
The latest from small and Emerging Pharma companies featuring Ray Therapeutics and Tortugas Neuroscience.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * Ray Therapeutics Raises $125…